Zai Lab (ZLAB) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Voting matters and shareholder proposals
Nine director nominees are up for re-election to serve until the 2027 annual general meeting, subject to earlier resignation or removal.
Appointment of KPMG LLP and KPMG as independent auditors for the year ending December 31, 2026, is up for approval.
Board authority to fix auditor compensation for 2026 is subject to shareholder approval.
Advisory vote on executive compensation for named executive officers is included.
Proposals include mandates to issue up to 10% new shares and to repurchase up to 10% of issued shares until the 2027 meeting.
Board of directors and corporate governance
Nine individuals are nominated for re-election to the board, with each recommended by the board.
Executive compensation and say-on-pay
Advisory approval is sought for the compensation of named executive officers as disclosed in the proxy statement.
Latest events from Zai Lab
- Q2 2026 revenue reached $106.3M, with 11% sequential growth and robust cash reserves.ZLAB
Q2 2026 - ZL-1310 demonstrates strong efficacy in small cell lung cancer, with pivotal trials and new assets advancing.ZLAB
Citi's 2025 Virtual Oncology Leadership Summit - ZL1310 demonstrates strong efficacy and safety in small cell lung cancer, advancing to phase III trials.ZLAB
American Society of Clinical Oncology Annual Meeting 2025 - Strong pipeline progress and commercialization plans position the company for major growth in China.ZLAB
Morgan Stanley 23rd Annual Global Healthcare Conference - All fourteen proposals, including director reelections and share mandates, were approved.ZLAB
AGM 2026 - Q1 2026 revenue fell 6% YoY to $99.6M; pipeline and launches support future growth.ZLAB
Q1 2026 - Proxy covers director elections, auditor appointments, compensation, share mandates, and ESG strategy.ZLAB
Proxy filing - Profitable China operations and rapid global pipeline progress drive growth and innovation.ZLAB
44th Annual J.P. Morgan Healthcare Conference - Q3 2024 revenue up 47% to $101.8M, net loss narrowed to $41.7M, with strong product growth.ZLAB
Q3 2024